Citations

Clear

1446 citation(s) found for "Howard, F".

Clinical value of CSF TMEM106B in familial and sporadic frontotemporal lobar degeneration
Wise, Amy B. , Li, Jingyao , Worringer, Katie, Heuer, Hilary W. , Ljubenkov, Peter A. , Staffaroni, Adam M. , Lago, Argentina Lario , Ramos, Eliana Marisa , Marks, J., Cook, Casey , Pernieel, Jolien, Rademakers, Rosa , Petrucelli, Leonard , Rosen, Howard J. , Boxer, Adam L. , ALLFTD, Rojas, Julio C. , Cobigo, Yann , Loureiro, Joseph , Worringer, Katie, VandeVrede, Lawren , Prudencio, Mercedes , Boeve, Bradley F. , ALLFTD

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S15 | Pages: No page available

10.1002/alz.080210 Get It

AbstractBackgroundTMEM106B, a lysosomal trafficking protein, is an important genetic susceptibility risk factor for frontotemporal lobar degeneration (FTLD). In GRN mutation carriers, minor allele homozygosity in the TMEM106B rs1990622 SNP modulates the risk of FTLD. TMEM106B is often the main component of amyloid fibrils in FTLD with TDP43 aggregates. TMEM106B has been quantified in human brain specimens, but its role as a fluid biomarker is unknown. Here, we investigate the clinical value of CSF TMEM106B in FTLD.MethodsCSF TMEM106B was quantified with SOMAmer proteomics (v3.0, SomaLogic®) in an original cohort of C9orf72, GRN and MAPT symptomatic and asymptomatic mutation carriers and family non‐carrier controls, recruited through ALLFTD (n = 182), and a validation cohort of sporadic neuropathology‐confirmed FTLD‐tau and FTLD‐TDP43, clinically‐diagnosed progressive supranuclear palsy – Richardson syndrome (PSP‐RS) and age‐matched controls (n = 96). CSF TMEM106B was correlated with disease severity, measured by the Frontotemporal Lobar Degeneration module global scores (CDR+NACC/FTLD); brain volume, measured with Bayesian linear mixed‐effect modeling, using age, sex and total‐intracranial volume‐corrected permutations with threshold‐free cluster enhancement; and CSF neurofilament light chain (NfL) measured with Simoa. TMEM106B SOMAmer specificity was validated in cell culture overexpression systems and human brain specimens with high TMEM106B burden.ResultsIn both cohorts, there were no differences in CSF TMEM106B by sex, phenotype or neuropathological diagnosis, except for lower levels in PSP‐RS compared to controls (‐0.31 Log2‐fold change, p < 0.001). CSF TMEM106B did not correlate with age. Regardless of disease‐causing mutation, lower CSF TMEM106B was associated with worse disease severity (Figure 1 and 2). CSF TMEM106B was lower in homozygous TMEM106B rs1990622 protective allelein C9orf2 and MAPT, but not in GRN mutation carriers (Figures 3). CSF TMEM106B showed a trend for inverse correlation with NfL in the whole sample (r = ‐0.135, p = 0.052), and correlated positively with left frontal volume in symptomatic FTLD mutation gene carriers (p < 0.05).ConclusionCSF TMEM106B is quantifiable in CSF in vivo. CSF TMEM106B levels are affected by an interaction of disease severity and FTLD and TMEM106B genotypes. Further work is needed to determine its value as a clinical biomarker.
Leveraging Large‐scale CSF Proteomics to identify Disease Progression Biomarkers in Autosomal Dominant Frontotemporal Lobar Degeneration
Staffaroni, Adam M. , Heuer, Hilary W. , Wise, Amy B. , Forsberg, Leah K. , Kramer, Joel H. , Li, Jingyao , Sivasankaran, Rajeev , Worringer, Katie, Rosen, Howard J. , Boxer, Adam L. , Casaletto, Kaitlin B. , Saloner, Rowan , Dammer, Eric B. , Johnson, Erik C. B. , Paolillo, Emily W. , Miller, Bruce L. , Loureiro, Joseph , Worringer, Katie, Boeve, Bradley F. , Rojas, Julio C.

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S14 | Pages: No page available

10.1002/alz.073417 Get It

AbstractBackgroundThe pathophysiological mechanisms driving frontotemporal lobar degeneration (FTLD) disease progression and corresponding biomarkers that capture these changes are not fully understood. We leveraged high‐throughput proteomics to identify networks of co‐expressed CSF proteins and candidate biomarkers for prediction of disease progression in adults with autosomal dominant FTLD mutations.Method113 adults carrying autosomal dominant FTLD mutations (C9orf72/GRN/MAPT) and 38 noncarrier controls from the ALLFTD consortium completed baseline lumbar puncture and longitudinal neuropsychological testing. CSF was assayed for SOMAmer proteomics on SOMAscan® v3.0 (4,140 proteins). Network analysis identified weighted protein co‐expression modules, which were annotated via gene ontology and cell‐type enrichment analysis. Disease age estimates that capture proximity to symptom onset were derived from a Bayesian disease progression model incorporating genotype‐specific clinical (cognition, CDR®+NACC FTLD) and biomarker (brain volume, plasma NfL) information. At baseline, local‐weighted regression examined module z‐scores (based on mean/SD of module levels [first principal component] in noncarriers) in relation to disease age. Longitudinal linear mixed‐effects models examined global cognitive trajectories in relation to baseline module z‐scores, as well as individual proteins within prognostic modules.ResultNetwork analysis identified 32 CSF protein co‐expression modules (37 to 223 proteins/module). 16 modules showed mutation‐related deviations from noncarriers. Deviations in ion transport, neurodevelopmental, metabolic, and transcriptional modules occurred several decades before estimated symptom onset (disease age: ‐30 to ‐20 years) and persisted across disease age. Deviations in neuroinflammatory and ubiquitination/autophagy modules occurred ∼10 years before estimated symptom onset. Sharp deviations in RNA binding, protein phosphorylation, neurogenesis, synaptic function, and lysosomal modules occurred near symptom onset (disease age: ‐1 to 4 years). Baseline synaptic and neurogenesis modules were the strongest prognosticators of cognitive decline (module x time: bs>.10, ps<.05). Within these modules, individual proteins with stronger intramodular connectivity exhibited stronger associations with cognitive decline (e.g., synaptic/transmembrane module: r = .40, p = 2.85e‐6; e.g., EPHA5, LRRTM2).ConclusionLarge‐scale analysis of the CSF proteome reveals a biologically‐diverse landscape of protein networks associated with presymptomatic and symptomatic stages of autosomal dominant FTLD. Synaptic and neuron‐enriched protein networks exhibited prodromal deviations that forecasted incipient cognitive decline. ‘Hub’ proteins derived from these affected networks warrant further validation as candidate biomarkers for early FTLD disease progression.
Functional connectivity trajectories in genetic frontotemporal dementia
Zhang, Liwen , Flagan, Taru , Staffaroni, Adam M. , Häkkinen, Suvi , Brown, Jesse A. , Mandelli, Maria Luisa , Rosen, Howard J. , Ramos, Eliana Marisa , Tempini, Maria Luisa Gorno , Lee, Suzee E. , Kantarci, Kejal , Miller, Bruce L. , Seeley, William W.

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S10 | Pages: No page available

10.1002/alz.081895 Get It

AbstractBackgroundCharacterizing disease trajectories in frontotemporal lobar degeneration (FTLD) is essential to determine the optimal timing for initiating therapeutic interventions, and there is an urgent need for novel and sensitive disease biomarkers. Intrinsic connectivity network (ICN) mapping using task‐free fMRI is a promising biomarker which reveals early abnormalities even before symptomatic onset (Dopper et al. 2014; Lee et al. 2016). Yet, ICN trajectories from the presymptomatic to symptomatic stages in FTLD mutation carriers remain unclear.MethodIn this cross‐sectional study, we used UCSF and ALLFTD Consortia data to study 129 carriers with variants in MAPT (presymptomatic/prodromal/symptomatic: 34/4/7), C9orf72 (30/9/12) and GRN (22/4/7). Using cross‐sectional data to construct ICN trajectories by genotype, we built separate generalized additive models for each genetic group to estimate non‐linear relationships between standardized connectivity changes and disease age across clinical stages. ICN connectivity was based on seed‐based analyses for networks associated with common clinical syndromes for each genetic group (i.e., salience and default mode [MAPT/C9orf72/GRN], corticobasal syndrome [MAPT/GRN], progressive supranuclear palsy syndrome [MAPT], sensorimotor and medial pulvinar‐related [C9orf72], and non‐fluent variant primary progressive aphasia (nfvPPA) syndrome networks [GRN]). We included 127 healthy controls as a reference to calculate ICN z‐scores for each carrier. Each carrier’s disease age was defined as the difference between the carrier’s chronological age and estimated age of onset based on multimodal measures of structural imaging, fluid biomarker and clinical assessments (Staffaroni et al. 2022).ResultIn MAPT+, presymptomatic carriers showed declining salience network connectivity starting approximately 30 years before estimated onset, which plateaued about 20 years before onset. In C9orf72+, salience network hyperconnectivity emerged about 30 years before onset and declined throughout the presymptomatic and symptomatic stages. For GRN+, connectivity changes as a function of disease age were found within the salience and nfvPPA networks, with connectivity stable until around 10 years before estimated onset, followed by decline starting in the late presymptomatic phase and continuing through the prodromal and symptomatic stages.ConclusionThese findings demonstrate that FTLD genes show distinct ICN trajectories throughout the clinical spectrum. These results help pave the way for determining the optimal timing to initiate therapeutic interventions.
Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States
Rencsok, Emily M. , Slopen, Natalie , McManus, Hannah D. , Autio, Karen A. , Morgans, Alicia K. , McSwain, Lawrence, Barata, Pedro C. , Cheng, Heather H. , Dreicer, Robert , Gerke, Travis , Green, Rebecca , Heath, Elisabeth I. , McKay, Rana R. , Nowak, Joel , Pileggi, Shannon , Pomerantz, Mark M., Whang, Young E. , Ragin, Camille , Vinson, Jake , Villanti, Paul , Haneuse, Sebastien , Mucci, Lorelei A. , George, Daniel J. , Registry, for the IRONMAN, Barata, Pedro , Howard, Lauren E , McKay, Rana R , Nowak, Joel , Pileggi, Shannon , Pomerantz, Mark M , Rathkopf, Dana E , Tagawa, Scott T , Whang, Young E , Ragin, Camille , Odedina, Folakemi , Kantoff, Philip W , Vinson, Jake , Villanti, Paul , Haneuse, Sebastien , Mucci, Lorelei A , George, Daniel J , Cheng, Heather H , Morgans, Alicia K , Dreicer, Robert , Howard, Lauren E. , Tagawa, Scott T. , Kantoff, Philip W. , Registry, for the IRONMAN

Mayo Clinic

Cancer Research Communications | December 18, 2023 | Volume: 4 | Issue: 1 | Pages: 55-64

10.1158/2767-9764.crc-23-0446 | PMID 38108490 Get It

Abstract Bone pain is a well-known quality-of-life detriment for individuals with prostate cancer and is associated with survival. This study expands previous work into racial differences in multiple patient-reported dimensions of pain and the association between baseline and longitudinal pain and mortality. This is a prospective cohort study of individuals with newly diagnosed advanced prostate cancer enrolled in the International Registry for Men with Advanced Prostate Cancer (IRONMAN) from 2017 to 2023 at U.S. sites. Differences in four pain scores at study enrollment by race were investigated. Cox proportional hazards models and joint longitudinal survival models were fit for each of the scale scores to estimate HRs and 95% confidence intervals (CI) for the association with all-cause mortality. The cohort included 879 individuals (20% self-identifying as Black) enrolled at 38 U.S. sites. Black participants had worse pain at baseline compared with White participants, most notably a higher average pain rating (mean 3.1 vs. 2.2 on a 10-point scale). For each pain scale, higher pain was associated with higher mortality after adjusting for measures of disease burden, particularly for severe bone pain compared with no pain (HR, 2.47; 95% CI: 1.44–4.22). The association between pain and all-cause mortality was stronger for participants with castration-resistant prostate cancer compared with those with metastatic hormone-sensitive prostate cancer and was similar among Black and White participants. Overall, Black participants reported worse pain than White participants, and more severe pain was associated with higher mortality independent of clinical covariates for all pain scales. Significance: Black participants with advanced prostate cancer reported worse pain than White participants, and more pain was associated with worse survival. More holistic clinical assessments of pain in this population are needed to determine the factors upon which to intervene to improve quality of life and survivorship, particularly for Black individuals.
Dual AApoAIV amyloidosis and ATTR amyloidosis arising in the same patient: a report of three cases
Dalland, Joanna , Dao, Linda N. , Dasari, Surendra , Theis, Jason D. , Chiu, April , Howard, Matthew T., Grogan, Martha , Hagen, Catherine E. , Bois, Melanie C. , Hagen, Catherine, Hagen, Catherine E , Rech, Karen L. , McPhail, Ellen Darcy

Mayo Clinic

Amyloid | December 15, 2023 | Volume: 31 | Issue: 2 | Pages: 153-155

10.1080/13506129.2023.2292949 | PMID 38099717 Get It

Frontal Osteomyelitis and Sinusitis Complication After Type III Frontal Bone Cranioplasty for Facial Feminization
Brown, Adam E. , Shrout, Max A., Howard, Brittany E.

Mayo Clinic

Facial Plastic Surgery & Aesthetic Medicine | December 15, 2023 | Volume: 26 | Issue: 1 | Pages: 79-82

10.1089/fpsam.2022.0397 | PMID 38100319 Get It

Background: Forehead contouring can be a component of facial feminization surgery (FFS). Its complications have been rarely reported on and are often described as “hypothetical.” Methods: A case report of complications from forehead contouring resulting in frontal osteomyelitis and sinusitis. Results: A female patient presented with frontal osteomyelitis, sinusitis, and forehead contour deformity after a type III forehead contouring surgery. She had failed prior treatment including oral antibiotics, IV antibiotics, revision sinus surgery, and revision nasal surgery. For definitive treatment, she underwent an anterior table resection, sinus obliteration with bony contouring, and pericranial flap. Conclusions: Forehead contouring represents a recent significant advancement in FFS and gender-affirming therapy. Descriptions of complications and their management are important when novel therapies such as FFS are introduced. This case demonstrates complications from type III forehead contouring including osteomyelitis, frontal sinusitis, and forehead deformity.
Baseline cognitive function among participants in the Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (Crest-2) (S50.007)
Lazar, Ronald M. , Wadley, Virginia G. , Voeks, Jenifer H. , Yuan, Ya , Lal, Brajesh K. , Heck, Donald , Jones, Michael , Brott, Thomas G. , Marshall, Randolph S. , Howard, George , Howard, Virginia J. , Meschia, James F.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.s50.007 Get It

Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis: Crest-2 (S50.006)
Lal, Brajesh K. , Roubin, Gary S., Brown, Robert R., Barrett, Kevin M. , Chimowitz, Marc I. , Lazar, Ronald M. , Moore, Wesley S. , Moy, Claudia S., Voeks, Jenifer H. , Brott, Thomas G. , Meschia, James F. , Howard, George , Chaturvedi, Seemant , Demaerschalk, Bart M. , Howard, Virginia J. , Huston, John , Turan, Tanya N.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.s50.006 Get It